Informed Consent for Ketamine Treatment: Essential Elements

Informed consent for ketamine treatment essential elements include a plain-language explanation of the proposed treatment, its approval status for the intended use, expected benefits, known risks, alternatives, monitoring, and the patient's right to decline or stop. Consent should be a conversation that continues as the treatment plan changes, not just a signature before the first dose.

Ketamine is an anesthetic medication that clinicians may prescribe at lower doses for some psychiatric or pain-related conditions. Racemic ketamine is FDA-approved as an anesthetic, while its psychiatric use is generally off-label. Esketamine nasal spray, sold as Spravato, is FDA-approved for certain depressive disorders and is subject to a Risk Evaluation and Mitigation Strategy, or REMS, program.

What informed consent should cover

The clinician should tailor the discussion to the person's diagnosis, route of administration, treatment setting, and medical history. A generic form cannot replace this conversation.

1. The treatment plan and approval status

Patients should understand which medication is proposed, how it will be given, where treatment occurs, who will monitor them, and the expected session schedule. For racemic ketamine used for depression or another psychiatric condition, the clinician should explain that this is an off-label use. Off-label prescribing means an approved drug is being prescribed for a use not included in its FDA-approved labeling.

For intranasal esketamine, the discussion should cover the approved indication that applies, if any, and the REMS requirements. The FDA states that Spravato must be administered under direct observation in a certified healthcare setting and that patients are monitored for at least two hours after administration. Read the FDA-approved Spravato prescribing information.

2. Expected benefit, including its limits

Consent should describe why ketamine is being considered and what a reasonable response may look like. Some research has found rapid symptom improvement in some people with treatment-resistant depression, but response is not assured, benefit can fade, and treatment is not presented as a cure. The American Psychiatric Association consensus statement notes that ketamine research has important limitations and calls for careful patient selection, monitoring, and risk discussion. Read the APA consensus statement on ketamine for mood disorders.

Patients considering treatment for severe depression should also discuss a safety plan and what to do if suicidal thoughts intensify. A rapid change in symptoms does not replace ongoing clinical assessment.

3. Common effects and meaningful risks

The consent discussion should distinguish expected short-term effects from less common or longer-term concerns. Ketamine can cause dissociation, changes in perception, dizziness, nausea, drowsiness, anxiety, headache, and temporary increases in blood pressure. The likely onset and duration depend on the route and dose.

Ketamine is a Schedule III controlled substance in the United States. That classification reflects recognized misuse potential and should prompt a discussion of substance use history, medication storage when applicable, and how the care team will watch for concerning use patterns. Repeated exposure may also warrant review for urinary symptoms, liver concerns, and cognitive effects, because long-term evidence at therapeutic doses remains limited.

For a practical overview of side effects to discuss with a clinician, see common ketamine side effects. People taking sedatives, alcohol, or other medications should also review potential interactions before treatment. This guide to ketamine drug interactions can help patients prepare questions for their prescriber.

Alternatives and the right to say no

Consent is informed only when alternatives are discussed in a way the patient can use. Depending on the condition and treatment history, options may include medication changes or augmentation, psychotherapy, electroconvulsive therapy, repetitive transcranial magnetic stimulation, intranasal esketamine, or no additional treatment at that time. The appropriate alternatives differ by patient.

Patients may decline ketamine, ask for more time, seek another clinical opinion, or stop a course of treatment. They should know how the treating clinician will support ongoing care if they choose another option. For people exploring next steps after difficult-to-treat depressionthis treatment-resistant depression guide outlines questions that may help structure that conversation.

How to make the conversation understandable

Clear consent uses ordinary language and checks understanding. Patients should be encouraged to explain back, in their own words, what the treatment is for, its main risks, the follow-up plan, and what choices remain available. Written material can help, especially when a person is distressed or processing a large amount of information.

Extra care is appropriate when severe depression, cognitive symptoms, acute crisis, or pressure from others may affect decision-making. Decision-making capacity generally involves understanding information, appreciating how it applies personally, reasoning about options, and communicating a choice. When capacity is uncertain, clinicians may need to assess it before proceeding.

Documenting and revisiting consent

A written record should identify the diagnosis or treatment goal, planned route and schedule, off-label status when relevant, expected benefits, material risks, alternatives, activity restrictions, monitoring, and the patient's questions and decision. It should also record the clinician's discussion and the date.

Consent should be revisited when the dose, route, frequency, setting, or clinical situation changes. It should also be revisited if meaningful new safety information emerges or if treatment moves from an initial series to maintenance care. Monitoring plans are part of that ongoing discussion, particularly for home-based or remote care. Read more about telehealth ketamine protocols before considering an at-home model.